Yu Deng

Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)

N. Reinmuth, Ying Cheng, A. Mansfield, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.

G. Giaccone, N. Reinmuth, R. Herbst, 2020, The New England journal of medicine.

Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial

A. Chella, H. Wakelee, N. Altorki, 2021, The Lancet.

Atezolizumab for First‐Line Treatment of Metastatic Nonsquamous NSCLC

Federico Cappuzzo, M. Socinski, F. Cappuzzo, 2018, The New England journal of medicine.

Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.

M. Socinski, F. Cappuzzo, T. Mok, 2019, The Lancet. Respiratory medicine.

Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non–Small-Cell Lung Cancer

M. Socinski, D. Moro-Sibilot, C. Barone, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

143TiPIMpower110: Phase III trial of 1L atezolizumab in PD-L1–selected chemotherapy-naive NSCLC

G. Giaccone, R. Herbst, J. Jassem, 2017 .

IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1–selected NSCLC

G. Giaccone, N. Reinmuth, R. Herbst, 2019, Annals of Oncology.

OA05.07 IMpower132: PFS and Safety Results with 1L Atezolizumab + Carboplatin/Cisplatin + Pemetrexed in Stage IV Non-Squamous NSCLC

S. Novello, V. Papadimitrakopoulou, P. Dubray-Longeras, 2018, Journal of Thoracic Oncology.

Patient-reported outcomes (PROs) in the randomized, phase III IMpower150 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous metastatic NSCLC (mNSCLC).

M. Socinski, A. Sandler, M. Reck, 2018 .